CtrlK
NVS
NYSE
Pharmaceuticals
$149.56
USD
-$4.20 (-2.73%)
At close: Jul 20, 2026, 4:00 PM EDT
Market Cap:
$281.56B
Volume:
1.8M
Previous Close
$153.76
Day Range
$149.33 - $153.54
52 Week Range
$112.34 - $170.46
Average Volume (10 Days)
2.3M
P/E Ratio (TTM)
20.87
Dividend Yield
3.07%
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
CEO
Dr. Vasant Narasimhan
Headquaters
Basel, BASEL-STADT, CH
Founded
2001
Employees
75,267
The FDA granted full approval for Novartis' Fabhalta to slow kidney function decline in adults with primary IgA nephropathy who are at risk of progression. This traditional approval represents a significant regulatory milestone for the treatment of this progressive kidney disease, expanding Novartis' portfolio of high-innovation medicines and supporting its strategic shift toward advanced therapies.